Medtronic PLC $MDT Position Reduced by Hedeker Wealth LLC

Key Points

• Hedeker Wealth LLC reduced its Medtronic position by 36.6% in the second quarter, selling 17,444 shares and retaining 30,282 shares valued at approximately $2.37 million. Institutional investors collectively own 82.06% of the company.
• Medtronic exceeded quarterly earnings and revenue expectations, reporting $1.55 in EPS and $9.81 billion in revenue, with revenue up 9.9% year over year. The company also raised its quarterly dividend to $0.72 per share, equivalent to a 3.1% yield.
• Analyst sentiment remains moderately positive, with a consensus “Moderate Buy” rating and a $98.83 price target, although several firms recently lowered their targets. Insider activity was negative, including an executive sale and no reported insider purchases over the past six months.

Hedeker Wealth LLC trimmed its position in Medtronic PLC (NYSE:MDT - Free Report) by 36.6% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 30,282 shares of the medical technology company's stock after selling 17,444 shares during the period. Hedeker Wealth LLC's holdings in Medtronic were worth $2,369,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in MDT. Anfield Capital Management LLC increased its position in shares of Medtronic by 410.7% during the 4th quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company's stock valued at $27,000 after purchasing an additional 230 shares during the period. Monetary Solutions Ltd acquired a new stake in shares of Medtronic in the fourth quarter valued at $27,000. Acumen Wealth Advisors LLC bought a new position in Medtronic during the fourth quarter valued at about $29,000. Imprint Wealth LLC bought a new position in Medtronic during the third quarter valued at about $31,000. Finally, Basepoint Wealth LLC acquired a new position in Medtronic during the fourth quarter worth about $32,000. 82.06% of the stock is owned by institutional investors.

Insider Activity at Medtronic

In related news, EVP Harry Skip Kiil sold 4,189 shares of the stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $80.44, for a total value of $336,963.16. Following the transaction, the executive vice president owned 37,227 shares in the company, valued at approximately $2,994,539.88. This represents a 10.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 0.26% of the company's stock.

Key Headlines Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic outperformed the broader market in the latest session, closing higher as investors focused on the company’s defensive medical-device exposure. Medtronic Advances While Market Declines
• Positive Sentiment: Seventeen analysts have issued targets over the past six months, with a median target of $101, implying additional upside from recent levels. Targets range widely, however, from $83 to $119. Medtronic Analyst Targets and Trading Data
• Neutral Sentiment: Value-focused coverage is comparing MDT with Agilent Technologies, indicating that investors are evaluating Medtronic’s valuation against peers rather than responding to a major new company-specific catalyst. MDT Versus Agilent for Value Investors
• Neutral Sentiment: Institutional positioning was mixed in the latest reported quarter: 998 investors increased holdings while 1,327 reduced positions, including sizable additions by JPMorgan and reductions by Capital Research and UBS. Medtronic Institutional Activity
• Negative Sentiment: Quiver estimated CEO Geoff Martha’s 2026 compensation at $22.9 million, up 7.4% year over year. It also reported eight open-market insider sales and no purchases over the past six months, which may raise governance and confidence concerns. Medtronic CEO Compensation and Insider Sales
• Negative Sentiment: BTIG reaffirmed a “buy” rating but set a $91 price target, below recent trading levels, signaling limited near-term upside in that analyst’s view. BTIG Reaffirms Medtronic Buy Rating

Medtronic Trading Up 1.8%

Shares of MDT opened at $92.22 on Wednesday. The business's 50-day moving average price is $83.60 and its 200 day moving average price is $86.13. The stock has a market capitalization of $118.04 billion, a P/E ratio of 24.72, a P/E/G ratio of 2.45 and a beta of 0.55. Medtronic PLC has a 1-year low of $73.31 and a 1-year high of $106.33. The company has a current ratio of 2.13, a quick ratio of 1.62 and a debt-to-equity ratio of 0.52.

Medtronic (NYSE:MDT - Get Free Report) last posted its quarterly earnings data on Wednesday, June 3rd. The medical technology company reported $1.55 EPS for the quarter, beating analysts' consensus estimates of $1.54 by $0.01. Medtronic had a net margin of 13.20% and a return on equity of 14.51%. The company had revenue of $9.81 billion during the quarter, compared to analyst estimates of $9.62 billion. During the same period in the prior year, the firm earned $1.62 earnings per share. The business's quarterly revenue was up 9.9% on a year-over-year basis. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. Analysts expect that Medtronic PLC will post 5.94 earnings per share for the current year.

Medtronic Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, July 17th. Stockholders of record on Friday, June 26th were issued a dividend of $0.72 per share. The ex-dividend date was Friday, June 26th. This represents a $2.88 annualized dividend and a dividend yield of 3.1%. This is an increase from Medtronic's previous quarterly dividend of $0.71. Medtronic's dividend payout ratio is presently 77.21%.

Analyst Upgrades and Downgrades

MDT has been the topic of several research reports. Needham & Company LLC reiterated a "buy" rating and issued a $101.00 price target on shares of Medtronic in a research report on Wednesday, June 17th. TD Cowen reduced their price objective on shares of Medtronic from $119.00 to $100.00 and set a "buy" rating for the company in a research report on Friday, July 10th. Truist Financial lowered their price objective on shares of Medtronic from $95.00 to $86.00 and set a "hold" rating on the stock in a research note on Thursday, June 4th. Stifel Nicolaus set a $80.00 target price on shares of Medtronic in a report on Wednesday, June 3rd. Finally, JPMorgan Chase & Co. cut their target price on shares of Medtronic from $100.00 to $86.00 and set a "neutral" rating for the company in a research note on Thursday, June 4th. Eighteen investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $98.83.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source